glp 1 study Real-world use of glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes: A retrospective database (DEFINE-G) GLP-1 Medications Get at the

Abstract Glucagon-like peptide-1 receptor agonists, originally developed for the treatment of metabolic disorders, have recently emerged as promising candidates for the management of substance use disorders

Hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess primary (MACE) and secondary outcomes (all-cause mortality, CV death, non-fatal MI, non-fatal stroke, and HF hospitalisation) between the two treatment groups

There is no strong clinical evidence favoring morning over evening

In retinal endothelial cells, activation of the GLP-1 receptor increases PI3K/Akt signaling, which activates endothelial nitric oxide synthase (eNOS), leading to NO production

2021;77:2334.e1

Researchers recommend that doctors have a deep understanding of someones mental health before that person starts a GLP-1 medication